NRx Pharmaceuticals price target raised to $25 from $21 at BTIG

BTIG analyst Thomas Shrader raised the firm’s price target on NRx Pharmaceuticals (NRXP) to $25 from $21 and keeps a Buy rating on the shares. The company is making progress on most fronts, and with FDA acceptance for the NDA detailing preservative-free ketamine, on-label option for MDD, Major Depressive Disorder, and ASIB, Acute Suicidal Ideation and Behavior, is the next important event, the analyst tells investors in a research note.